Organogenesis Holdings Inc.ORGO

時価総額
$6.7億
PER
再生医療製品の大手。Apligraf、Dermagraft、PuraPlyなどの皮膚代替製品を展開。2024年11月12日のシリーズA優先株で1.3億ドルを調達、7,921,731株の株式買戻し。米国中心に研究生産拠点を保有し、2024年12月31日時点で従業員約869人。
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
2024年
12月31日
Cash and cash equivalents-----114102104136
Restricted cash--0001101
Accounts Receivable, after Allowance for Credit Loss, Current--343957828982110
Inventory, Net--13232825252826
Prepaid expenses and other current assets--235551014
Total current assets1294,43971126174227223225286
Property and equipment, net--4047607910211689
Intangible assets, net--26213126211612
Goodwill--26262929292929
Operating Lease, Right-of-Use Asset-----49434037
Deferred tax asset, net----032302839
Other assets--1112265
Total assets311313164221294443449460498
Secured Debt, Current----17355-
Finance Lease, Liability, Current-----0-11
Current portion of operating lease obligations related party-------34
Operating Lease, Liability, Current-----1212104
Accounts payable--19282329323129
Accrued expenses and other current liabilities--25232437263039
Total current liabilities478,360466606882758177
Term loan, net of current portion----43716661-
Finance Lease, Liability, Noncurrent-------21
Operating Lease, Liability, Noncurrent related party-------178
Operating Lease, Liability, Noncurrent-----47412025
Other liabilities--1782111
Total liabilities1115117165148201184181113
Temporary Equity, Carrying Amount, Attributable to Parent295293------122
Common Stock, Value, Issued--0000000
Additional paid-in capital57177227299302311320303
Accumulated deficit-233,860-2,327,773-130-171-153-60-45-41-40
Total stockholders' equity554756146242266279263
Total liabilities, redeemable convertible preferred stock, and stockholders' equity311313164221294443449460498